SCHEMBL16070248

SCHEMBL16070248

CCN(CC)CCc1cccc(Nc2ncc(OCc3cc(C(=O)NC)cc(OC)c3F)cn2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 3/20 0.38
▸ FGFR4 P22455 3/20 0.38
▸ PTK2 Q05397 2/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CDK2 P24941 5/20 0.37
▸ CDK9 P50750 5/20 0.37
▸ FGFR3 P22607 2/20 0.36
▸ IGF1R P08069 2/20 0.36
▸ SIRT2 Q8IXJ6 1/20 0.36
▸ SIRT1 Q96EB6 1/20 0.36
▸ SIRT3 Q9NTG7 1/20 0.36
▸ FGFR2 P21802 1/20 0.36
▸ ALKBH1 Q13686 1/20 0.36
▸ CCNT1 O60563 2/20 0.36
▸ CCNE1 P24864 2/20 0.36
▸ SYK P43405 2/20 0.36
▸ CCNK O75909 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16070348 0.85 PTK2 (0.51) FGFR1FGFR4PTK2CYP3A4CYP2D6
SCHEMBL16070511 0.85 ABL1 (0.44) PTK2SRC
SCHEMBL16070195 0.83 SCN9A (0.44) FGFR1FGFR4FGFR3FGFR2
SCHEMBL16070213 0.83 PTK2 (0.40) FGFR1FGFR4PTK2CYP3A4CYP2D6
SCHEMBL16070363 0.83 POLB (0.44) FGFR1FGFR4PTK2CYP3A4CYP2D6
SCHEMBL16070358 0.81 FGFR3 (0.47) FGFR1FGFR4PTK2CYP3A4CYP2D6
SCHEMBL16070347 0.81 SCN9A (0.41) FGFR1FGFR4PTK2CYP3A4CYP2D6
SCHEMBL16070502 0.81 CDK9 (0.46) FGFR1FGFR4PTK2CYP3A4CYP2D6
SCHEMBL16069763 0.81 FGFR3 (0.55) FGFR1FGFR4FGFR3FGFR2ALKBH1
SCHEMBL16069792 0.81 PTK2 (0.44) FGFR1FGFR4PTK2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701680-B2 Pyrimidine and pyridine compounds and their usage HUTCHISON MEDIPHARMA LIMITED (CN) 2017-07-11 — — US disclosed
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2016-01-28 — — US disclosed
WO-2014139465-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE HUTCHISON MEDIPHARMA LIMITED (CN) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024021-A1 NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE FGFR3, FGFR1, FGFR4 FGFR1 2/4885FGFR4 3/4885PTK2 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback